Table 1:
Patient characteristics of the Training cohort.
| (n = 108) | |
|---|---|
| Clinical characteristics | |
| Sex, n (%) | |
| Male | 73 (67.6) |
| Female | 34 (31.5) |
| Unknown | 1 (0.9) |
| Age | |
| Known, n (%) | 103 (95.4) |
| Median, n (range) | 67 (22–96) |
| Unknown, n (%) | 5 (4.6) |
| Location of tumor, n (%) | |
| Trunk | 58 (53.7) |
| Extremity | 48 (44.4) |
| Unknown | 2 (1.9) |
| T-stage, n (%) | |
| T1a or T1b | 18 (16.7) |
| T2a | 11 (10.2) |
| T2b or T3a | 41 (38.0) |
| T3b or T4a | 22 (20.4) |
| T4b | 12 (11.1) |
| Unknown | 4 (3.7) |
| Stage, n (%) | |
| I | 22 (20.4) |
| II | 62 (57.4) |
| III | 24 (22.2) |
| Pathologic characteristics | |
| Depth (mm) | |
| Median, n (range) | 2.30 (0.30–30) |
| Ulceration, n (%) | |
| Absent | 57 (52.8) |
| Present | 47 (43.5) |
| Unknown | 4 (3.7) |
| Microsatellite lesions, n (%) | |
| Absent | 101 (93.5) |
| Present | 6 (5.6) |
| Unknown | 1 (0.9) |
| TILs | |
| Absent | 9 (8.3) |
| Non-brisk | 67 (62.0) |
| Brisk | 23 (21.3) |
| Unknown | 9 (8.3) |
| SLNB status, n (%) | |
| Completed | 66 (61.1) |
| Positive, n (% of completed) | 20 (18.5) |
| Negative, n (% of completed) | 46 (42.6) |
| Not completed | 15 (13.9) |
| SLNB status unknown | 27 (25) |
| Outcome characteristics | |
| Patient follow-up (months) | |
| Median, n (range) | 58 (7–173) |
| DMR, n (%) | |
| Distant recurrence | 34 (31.5) |
| No recurrence or local recurrence only | 74 (68.5) |
| OS, n (%) | |
| Alive (at least 2 years) | 69 (63.9) |
| Dead | 39 (36.1) |
| DSS, n (%) | |
| Alive or NED at death | 78 (72.2) |
| Median follow-up (months) | 65 |
| Dead with melanoma | 30 (27.8) |
| Median follow-up (months) | 34.5 |
| Unknown | 0 (0) |
Abbreviations: DMR, distant metastatic recurrence; DSS, disease-specific survival; NED, no evidence of disease; OS, overall survival